Cargando…
Role of CC-chemokine ligand 2 in gynecological cancer
Gynecological cancer is one of the most severe diseases that threaten the lives and health of women worldwide. Its incidence rate increases with each passing year and becomes more prevalent among young people. The prognosis of gynecological cancer remains poor despite significant advances in surgica...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675065/ https://www.ncbi.nlm.nih.gov/pubmed/36403055 http://dx.doi.org/10.1186/s12935-022-02763-z |
_version_ | 1784833280250478592 |
---|---|
author | Zhang, Jia-Jia Liu, Wei Xing, Guo-Zhen Xiang, Li Zheng, Wen-Ming Ma, Zhen-Ling |
author_facet | Zhang, Jia-Jia Liu, Wei Xing, Guo-Zhen Xiang, Li Zheng, Wen-Ming Ma, Zhen-Ling |
author_sort | Zhang, Jia-Jia |
collection | PubMed |
description | Gynecological cancer is one of the most severe diseases that threaten the lives and health of women worldwide. Its incidence rate increases with each passing year and becomes more prevalent among young people. The prognosis of gynecological cancer remains poor despite significant advances in surgical removal and systemic chemotherapy. Several chemokines play a role in the progression of gynecologic cancers. CCL2 (CC-chemokine ligand 2), also termed MCP-1 (monocyte chemotactic protein 1), plays a significant physiological role in monocyte cell migration and the inflammatory response. Recent studies have demonstrated that CCL2 plays a pro-tumorigenic function in the tumor microenvironment. According to previous studies, CCL2 plays a significant role in the occurrence and development of gynecological cancers. Furthermore, recent studies noted that CCL2 could be a potential diagnostic biomarker and prognostic predictor. The purpose of this paper is to review the role of CCL2 in the occurrence and development of gynecological cancers and to discuss the potential therapeutic strategy of CCL2 for gynecological cancers, with a primary focus on breast cancer, ovarian cancer, cervical cancer, and endometrial cancer. |
format | Online Article Text |
id | pubmed-9675065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96750652022-11-20 Role of CC-chemokine ligand 2 in gynecological cancer Zhang, Jia-Jia Liu, Wei Xing, Guo-Zhen Xiang, Li Zheng, Wen-Ming Ma, Zhen-Ling Cancer Cell Int Review Gynecological cancer is one of the most severe diseases that threaten the lives and health of women worldwide. Its incidence rate increases with each passing year and becomes more prevalent among young people. The prognosis of gynecological cancer remains poor despite significant advances in surgical removal and systemic chemotherapy. Several chemokines play a role in the progression of gynecologic cancers. CCL2 (CC-chemokine ligand 2), also termed MCP-1 (monocyte chemotactic protein 1), plays a significant physiological role in monocyte cell migration and the inflammatory response. Recent studies have demonstrated that CCL2 plays a pro-tumorigenic function in the tumor microenvironment. According to previous studies, CCL2 plays a significant role in the occurrence and development of gynecological cancers. Furthermore, recent studies noted that CCL2 could be a potential diagnostic biomarker and prognostic predictor. The purpose of this paper is to review the role of CCL2 in the occurrence and development of gynecological cancers and to discuss the potential therapeutic strategy of CCL2 for gynecological cancers, with a primary focus on breast cancer, ovarian cancer, cervical cancer, and endometrial cancer. BioMed Central 2022-11-19 /pmc/articles/PMC9675065/ /pubmed/36403055 http://dx.doi.org/10.1186/s12935-022-02763-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Zhang, Jia-Jia Liu, Wei Xing, Guo-Zhen Xiang, Li Zheng, Wen-Ming Ma, Zhen-Ling Role of CC-chemokine ligand 2 in gynecological cancer |
title | Role of CC-chemokine ligand 2 in gynecological cancer |
title_full | Role of CC-chemokine ligand 2 in gynecological cancer |
title_fullStr | Role of CC-chemokine ligand 2 in gynecological cancer |
title_full_unstemmed | Role of CC-chemokine ligand 2 in gynecological cancer |
title_short | Role of CC-chemokine ligand 2 in gynecological cancer |
title_sort | role of cc-chemokine ligand 2 in gynecological cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675065/ https://www.ncbi.nlm.nih.gov/pubmed/36403055 http://dx.doi.org/10.1186/s12935-022-02763-z |
work_keys_str_mv | AT zhangjiajia roleofccchemokineligand2ingynecologicalcancer AT liuwei roleofccchemokineligand2ingynecologicalcancer AT xingguozhen roleofccchemokineligand2ingynecologicalcancer AT xiangli roleofccchemokineligand2ingynecologicalcancer AT zhengwenming roleofccchemokineligand2ingynecologicalcancer AT mazhenling roleofccchemokineligand2ingynecologicalcancer |